Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16745483 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL16745482 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL16745484 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL18994197 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL16745479 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL23250849 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL16745469 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL16745470 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL15895211 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL14147723 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682990-B2 | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682990-B2 | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160318946-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-9328073-B2 | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150148370-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318946-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | TOP1, TOP2A, TOP2B | LMNA 664/4885L3MBTL1 4386/4885TDP1 15/4885 |
| US-20150148370-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | TOP1, TOP2A, TOP2B | LMNA 664/4885L3MBTL1 4386/4885TDP1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.